FOXO1 and prostate cancer: The FOXO1 analog peptide can be combined with IQGAP1 as endogenous FOXO1, inhibiting feedback activation of ERK upon transfection of FOXO1, and improving the sensitivity of prostate cancer cells to PI3K inhibitors and paclitaxel (141).